Lynx1 Capital Management »

Autolus Therapeutics Plc spon ads shares owned by Lynx1 Capital Management

Quarter-by-quarter ownership of Autolus Therapeutics Plc spon ads (AUTL) shares owned by Lynx1 Capital Management from 13F filings

Historical chart of Lynx1 Capital Management investment in Autolus Therapeutics Plc spon ads

Tip: Access up to 7 years of quarterly data

All positions including Autolus Therapeutics Plc spon ads held by Lynx1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Autolus Therapeutics Plc spon ads by Lynx1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $12M 1.9M 6.44
2023-09-30 $3.2M 1.4M 2.33

More positions owned by Lynx1 Capital Management

Alpine Immune Sciences (ALPN)
Cabaletta Bio (CABA)
Merus N V (MRUS)
Tscan Therapeutics (TCRX)
C4 Therapeutics Com Stk (CCCC)
Stoke Therapeutics (STOK)
Autolus Therapeutics Spon Ads (AUTL)
Gh Research Ordinary Shares (GHRS)
Kinnate Biopharma (KNTE)
Silence Therapeutics Ads (SLN)
Theseus Pharmaceuticals
Pieris Pharmaceuticals (PIRS)
Bionomics Ads (BNOX)
Nektar Therapeutics (NKTR)
Passage Bio (PASG)

View all positions for Lynx1 Capital Management

Top funds holding Autolus Therapeutics Plc spon ads

Syncona Portfolio
Blackstone Group
Paradigm Biocapital Advisors
Polygon Management
Cormorant Asset Management
Frazier Life Sciences Management
T. Rowe Price Associates
Perpetual
Lynx1 Capital Management
Perceptive Advisors
Bank of New York Mellon
Fred Alger Management
Laurion Capital Management
Walleye Trading Advisors
Alphabet

View all funds holding Autolus Therapeutics Plc spon ads